These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 32385234)
1. Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms. Duarte DP; Lamontanara AJ; La Sala G; Jeong S; Sohn YK; Panjkovich A; Georgeon S; Kükenshöner T; Marcaida MJ; Pojer F; De Vivo M; Svergun D; Kim HS; Dal Peraro M; Hantschel O Nat Commun; 2020 May; 11(1):2319. PubMed ID: 32385234 [TBL] [Abstract][Full Text] [Related]
2. Six X-linked agammaglobulinemia-causing missense mutations in the Src homology 2 domain of Bruton's tyrosine kinase: phosphotyrosine-binding and circular dichroism analysis. Mattsson PT; Lappalainen I; Bäckesjö CM; Brockmann E; Laurén S; Vihinen M; Smith CI J Immunol; 2000 Apr; 164(8):4170-7. PubMed ID: 10754312 [TBL] [Abstract][Full Text] [Related]
3. Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA). Zhu Q; Zhang M; Rawlings DJ; Vihinen M; Hagemann T; Saffran DC; Kwan SP; Nilsson L; Smith CI; Witte ON; Chen SH; Ochs HD J Exp Med; 1994 Aug; 180(2):461-70. PubMed ID: 7519238 [TBL] [Abstract][Full Text] [Related]
4. Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling. Hashimoto S; Iwamatsu A; Ishiai M; Okawa K; Yamadori T; Matsushita M; Baba Y; Kishimoto T; Kurosaki T; Tsukada S Blood; 1999 Oct; 94(7):2357-64. PubMed ID: 10498607 [TBL] [Abstract][Full Text] [Related]
5. Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane. Wang Q; Pechersky Y; Sagawa S; Pan AC; Shaw DE Proc Natl Acad Sci U S A; 2019 May; 116(19):9390-9399. PubMed ID: 31019091 [TBL] [Abstract][Full Text] [Related]
6. A regulatory SH2 domain-targeting protein binder effectively inhibits the activity of Bruton's tyrosine kinase and its drug-resistant variants. Jeong S; Sohn YK; Choi Y; Park J; Kim HS Biochem Biophys Res Commun; 2020 May; 526(1):8-13. PubMed ID: 32192770 [TBL] [Abstract][Full Text] [Related]
7. Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia. Tzeng SR; Pai MT; Lung FD; Wu CW; Roller PP; Lei B; Wei CJ; Tu SC; Chen SH; Soong WJ; Cheng JW Protein Sci; 2000 Dec; 9(12):2377-85. PubMed ID: 11206059 [TBL] [Abstract][Full Text] [Related]
8. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
9. Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Li T; Tsukada S; Satterthwaite A; Havlik MH; Park H; Takatsu K; Witte ON Immunity; 1995 May; 2(5):451-60. PubMed ID: 7538439 [TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and prenatal diagnosis for 22 families in Henan Province of China with X-linked agammaglobulinemia (XLA) related to Bruton's tyrosine kinase (BTK) gene mutations. Gao S; Hu S; Duan H; Wang L; Kong X BMC Med Genet; 2020 Jun; 21(1):131. PubMed ID: 32552675 [TBL] [Abstract][Full Text] [Related]
11. Screening and Characterization of Allosteric Small Molecules Targeting Bruton's Tyrosine Kinase. Kueffer LE; Lin DY; Amatya N; Serrenho J; Joseph RE; Courtney AH; Andreotti AH Biochemistry; 2024 Jan; 63(1):94-106. PubMed ID: 38091504 [TBL] [Abstract][Full Text] [Related]
13. Molecular and structural characterization of five novel mutations in the Bruton's tyrosine kinase gene from patients with X-linked agammaglobulinemia. Saha BK; Curtis SK; Vogler LB; Vihinen M Mol Med; 1997 Jul; 3(7):477-85. PubMed ID: 9260159 [TBL] [Abstract][Full Text] [Related]
14. Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA). Vihinen M; Mattsson PT; Smith CI Front Biosci; 2000 Dec; 5():D917-28. PubMed ID: 11102316 [TBL] [Abstract][Full Text] [Related]
15. Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. Hyvönen M; Saraste M EMBO J; 1997 Jun; 16(12):3396-404. PubMed ID: 9218782 [TBL] [Abstract][Full Text] [Related]
16. Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia. Brunner C; Kreth HW; Ochs HD; Schuster V J Clin Immunol; 2002 Jul; 22(4):244-51. PubMed ID: 12148599 [TBL] [Abstract][Full Text] [Related]
17. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164 [TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. de Weers M; Mensink RG; Kraakman ME; Schuurman RK; Hendriks RW Hum Mol Genet; 1994 Jan; 3(1):161-6. PubMed ID: 8162018 [TBL] [Abstract][Full Text] [Related]
19. BTK, the tyrosine kinase affected in X-linked agammaglobulinemia. Vihinen M; Mattsson PT; Smith CI Front Biosci; 1997 Jan; 2():d27-42. PubMed ID: 9159207 [TBL] [Abstract][Full Text] [Related]
20. Impact of amino acid substitution in the kinase domain of Bruton tyrosine kinase and its association with X-linked agammaglobulinemia. Mohammad T; Amir M; Prasad K; Batra S; Kumar V; Hussain A; Rehman MT; AlAjmi MF; Hassan MI Int J Biol Macromol; 2020 Dec; 164():2399-2408. PubMed ID: 32784026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]